BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25048202)

  • 1. Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.
    Li J; Kang Y; Wei L; Liu W; Tian Y; Chen B; Lin X; Li Y; Feng GS; Lu Z
    PLoS One; 2014; 9(7):e102847. PubMed ID: 25048202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP2 inhibitor PHPS1 protects against atherosclerosis by inhibiting smooth muscle cell proliferation.
    Chen J; Cao Z; Guan J
    BMC Cardiovasc Disord; 2018 Apr; 18(1):72. PubMed ID: 29703160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors.
    Madak-Erdogan Z; Kieser KJ; Kim SH; Komm B; Katzenellenbogen JA; Katzenellenbogen BS
    Mol Endocrinol; 2008 Sep; 22(9):2116-27. PubMed ID: 18617595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability
    Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R
    Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401
    [No Abstract]   [Full Text] [Related]  

  • 5. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
    Pietras RJ; Márquez DC; Chen HW; Tsai E; Weinberg O; Fishbein M
    Steroids; 2005; 70(5-7):372-81. PubMed ID: 15862820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus.
    Yang LC; Zhang QG; Zhou CF; Yang F; Zhang YD; Wang RM; Brann DW
    PLoS One; 2010 May; 5(5):e9851. PubMed ID: 20479872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a membrane-associated estrogen receptor in breast cancer cells and its contribution to hormone therapy resistance using a novel selective ligand.
    Niwa T; Takanobu J; Suzuki K; Sato Y; Yamaguchi Y; Hayashi SI
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105671. PubMed ID: 32289430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
    Schramm C; Edwards MA; Krenz M
    J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP2 inhibitor PHPS1 ameliorates acute kidney injury by Erk1/2-STAT3 signaling in a combined murine hemorrhage followed by septic challenge model.
    Jiang J; Hu B; Chung CS; Chen Y; Zhang Y; Tindal EW; Li J; Ayala A
    Mol Med; 2020 Sep; 26(1):89. PubMed ID: 32957908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
    Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
    Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.
    Hellmuth K; Grosskopf S; Lum CT; Würtele M; Röder N; von Kries JP; Rosario M; Rademann J; Birchmeier W
    Proc Natl Acad Sci U S A; 2008 May; 105(20):7275-80. PubMed ID: 18480264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of Breast Cancer Preventive Action of Pomegranate: Disruption of Estrogen Receptor and Wnt/β-Catenin Signaling Pathways.
    Mandal A; Bishayee A
    Molecules; 2015 Dec; 20(12):22315-28. PubMed ID: 26703530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase.
    Greger JG; Fursov N; Cooch N; McLarney S; Freedman LP; Edwards DP; Cheskis BJ
    Mol Cell Biol; 2007 Mar; 27(5):1904-13. PubMed ID: 17194752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2.
    Jiang K; Yang Z; Cheng L; Wang S; Ning K; Zhou L; Lin J; Zhong H; Wang L; Li Y; Huang J; Zhang H; Ye Q
    J Biol Chem; 2013 Aug; 288(34):24590-9. PubMed ID: 23861392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine phosphatase SHP2 regulates the expression of acyl-CoA synthetase ACSL4.
    Cooke M; Orlando U; Maloberti P; Podestá EJ; Cornejo Maciel F
    J Lipid Res; 2011 Nov; 52(11):1936-48. PubMed ID: 21903867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells.
    Lee YM; Lee JY; Ho CC; Hong QS; Yu SL; Tzeng CR; Yang PC; Chen HW
    Breast Cancer Res; 2011; 13(6):R116. PubMed ID: 22113133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer.
    Chen H; Libring S; Ruddraraju KV; Miao J; Solorio L; Zhang ZY; Wendt MK
    Oncogene; 2020 Dec; 39(49):7166-7180. PubMed ID: 33033382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.